Sun Pharma launches CEQUA®, a novel therapy for Dry Eye Disease in India
 
First  dry  eye  treatment  available  in  India  that  is  delivered  with  nanomicellar  (NCELL ® ) *  Technology    Unique  NCELL ®*  Technology  and  formulation  provides  superior  delivery  over  cyclosporine  emulsion  0.05% i Backed  by  several  years  of  clinical  experience  in  the  U.S.  and  other  geographies. Mumbai, India, April 25, 2023 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO,  Bloomb: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries  and/or associate companies) today announced that one of its wholly-owned subsidiaries has  launched a novel ophthalmology treatment, CEQUA ® , in India for patients who have Dry Eye  Disease  (DED)  with  inflammation,  a  commonly  occurring  condition.  CEQUA ®  is  the  first  dry  eye   treatment  available  in  India  that  is  delivered  with  nanomicellar  (NCELL ® ) *  technology.       Kirti Ganorkar, CEO – India Business, Sun Pharma, said, “Current treatment optio...
 
 
